

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/522,753	03/10/2000	Ronald M. Evans	SALK1510-3	4924
30542 75	90 05/23/2005	•	EXAM	INER
FOLEY & LA	RDNER		LEFFERS JR,	GERALD G
P.O. BOX 8027 SAN DIEGO.	'8 CA 92138-0278		ART UNIT	PAPER NUMBER
57.11 × 21200,	011 /2:00 02/0		1636	

DATE MAILED: 05/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)										
	09/522,753	EVANS ET AL.										
Office Action Summary	Examiner	Art Unit										
	Gerald G. Leffers Jr., PhD	1636										
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address										
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).												
Status		•										
1) Responsive to communication(s) filed on 15 Fe	ebruary 2005.											
,-	action is non-final.											
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.												
Disposition of Claims												
4) ⊠ Claim(s) 3-5, 9-10, 12-14, 16-25 & 38 is/are per 4a) Of the above claim(s) is/are withdraw 5) ⊠ Claim(s) 9,10,12,13,17 and 38 is/are allowed. 6) □ Claim(s) 4,5,14,16,18,19,21-25 is/are rejected. 7) ⊠ Claim(s) 3 and 20 is/are objected to.	4) ⊠ Claim(s) 3-5, 9-10, 12-14, 16-25 & 38 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ⊠ Claim(s) 9,10,12,13,17 and 38 is/are allowed. 6) □ Claim(s) 4,5,14,16,18,19,21-25 is/are rejected. 7) ⊠ Claim(s) 3 and 20 is/are objected to.											
Application Papers												
9) The specification is objected to by the Examine	r.											
10)☐ The drawing(s) filed on is/are: a)☐ acc	epted or b) \square objected to by the E	Examiner.										
Applicant may not request that any objection to the	• • • • • • • • • • • • • • • • • • • •											
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex												
Priority under 35 U.S.C. § 119												
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.												
Attachment(s)	_											
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) ☐ Interview Summary Paper No(s)/Mail Da 5) ☐ Notice of Informal P 6) ☑ Other: ☑ Lot of A	(PTO-413) ate latent Application (PTO-152) (SEARCL Raport SEQID MO:5)										

Application/Control Number: 09/522,753

Art Unit: 1636

DETAILED ACTION

Response to Amendment

Receipt is acknowledged of a supplementary response, filed 2/15/2005, in which the response explicitly answered each of the grounds of rejection made in the previous office action mailed on 4/20/2004. In the original response to the previous office action, filed on 8/12/2004, several claims were amended (claims 4, 5, 9, 12, 14, 23 and 25). Claims 3-5, 9-10, 12-14, 16-25 & 38 are pending and under consideration in the instant application.

Any rejection of record not addressed herein is withdrawn. This action is not final as there are new grounds of rejection presented herein that were not necessitated by applicants' amendment of the claims in the response filed on 8/12/2004.

Priority

Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120 as follows:

The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application); the disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The prior application to which the instant application seeks priority is U.S. Application Serial No. 08/522,726, filed 9/1/1995 (now U.S. Patent No. 6,489,441). The '726 application discloses only 3 sequences that correspond to SEQ ID NOS: 1-

Application/Control Number: 09/522,753

Art Unit: 1636

3 of the instant application. Each of the pending claims is directed to an isolated polynucleotide that (i) has a recited percent identity to one of SEQ ID NOS: 4, 6, & 8; or (ii) encodes a polypeptide having a recited percent identity to one of SEQ ID NOS: 5, 7 & 9. The prior application does not disclose these particular sequences. Therefore, the prior application does not provide support for the broadly recited genus of polynucleotides encompassed by the pending claims. Accordingly, the priority date for the pending claims is the filing date of the instant application (3/10/2000).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 4, 19, 21-22 are rejected under 35 U.S.C. 102(b) as being anticipated by Chen et al (Nature, October 1995, Vol. 377, No. 6548, pages 454-457; see the entire reference). This is a new rejection.

Chen et al teach the identification and characterization of a transcriptional co-repressor that is an SMRT (i.e. silencing mediator for retinoid and thyroid hormone receptors). The SMRT polypeptide taught by Chen et al is encoded by a polynucleotide sequence that encodes a polypeptide that is ~94% identical to the sequence of SEQ ID NO: 5 (see the attached Exhibit A,

Art Unit: 1636

result #6 for accession number HSU37146). Thus, the polynucleotide sequence taught by Chen et al anticipates the broad genus of polynucleotides encompassed by the instant claims.

Claims 4, 19, 21-22 are rejected under 35 U.S.C. 102(a) as being anticipated by Ordentlich et al (PNAS USA, 16 March 1999, Vol. 96, No. 6, pages 2639-2644; see the entire reference). This is a new rejection.

Ordentlich et al teach unique forms of the human and mouse nuclear receptor corepressor SMRT. In particular, Ordentlich et al teach nucleic acids, described by accession numbers AF113003 & AF113001, that encode polypeptides with 100% & 88.2% identity with SEQ ID NO: 5, respectively (e.g. see results 1 & 3 of the search report provided as Exhibit A).

Claims 4, 19, 21-22 are rejected under 35 U.S.C. 102(a) as being anticipated by Park et al (PNAS USA, 30 March 1999, Vol. 96, No. 7, pages 3519-3524; see the entire reference). This is a new rejection.

Park et al teach the identification of an extended isoform of SMRT termed SMRTe by the authors. In particular, Park et al teach nucleic acids, described by accession numbers AF125672 & AF125671, that encode polypeptides with ~98% and ~82% identity with SEQ ID NO: 5 (e.g. see results 2 & 4 of the search report provided as Exhibit A).

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it

Application/Control Number: 09/522,753

Art Unit: 1636

pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 5 & 18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new rejection.

Claim 5 is directed to an isolated polynucleotide encoding an SMRT co-repressor, or a peptide portion thereof, where the SMRT co-repressor or peptide portion thereof is capable of mediating the transcriptional silencing of at least one member of the steroid/thyroid hormone superfamily of receptors. The claim then recites the limitation of "... wherein said SMRT corepressor or peptide portion thereof is encoded by a polynucleotide having at least 80% sequence identity with SEQ ID NO: 4". This latter recitation appears to specify that the polynucleotide having at least 80% identity to SEQ ID NO: 4 is a different polynucleotide from the one that is actually claimed. As such, the nucleotide that is actually claimed can be any nucleotide that encodes the same SMRT protein, or portion thereof, that is encoded by the second nucleotide sequence (e.g. the first polynucleotide encodes the SMRT protein, or portion thereof, and which is different from the second polynucleotide because of the degeneracy of the genetic code and/or because the two different polynucleotides comprise additional, different sequences from one another). There does not appear to be support anywhere in the originally filed specification or claims for this formulation. Therefore, the phrase "... wherein said SMRT co-repressor or peptide portion thereof is encoded by a polynucleotide having at least 80% sequence identity with SEQ ID NO: 4" is impermissible NEW MATTER.

Application/Control Number: 09/522,753 Page 6

Art Unit: 1636

Claims 23-25 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a new rejection necessitated by applicants' amendment of the claims in the response filed on 8/12/2004.

Claim 23 is directed to a genus of oligonucleotides that are identifiable under "suitable stringency conditions" with respect to other nucleic acid sequences. The term "suitable stringency conditions" is used in the context of an identified oligonucleotide comprising at least 15 nucleotides that hybridizes to a polynucleotide of claim 4, but not to a polynucleotide encoding SEQ ID NO: 11 or to a polynucleotide encoding an amino acid sequence consisting of amino acids 1031 to 2517 of SEQ ID NO: 5. The specification does not define these exact conditions and the skilled artisan has no basis to visualize what these "suitable" conditions might be. Similarly, claim 25 specifies that the oligonucleotide of claim 23 hybridizes under "suitable stringency conditions" to a polynucleotide encoding SEQ ID NO: 5 or SEQ ID NO: 7, but does not hybridize to a polynucleotide encoding SEQ ID NO: 9. Again, the exact hybridization conditions are not described. Thus, the rejected claims comprise a genus of oligonucleotides that must meet very particular hybridization requirements, yet there is no description of the hybridization conditions that will necessarily identify an oligonucleotide having the recited functional activity.

Application/Control Number: 09/522,753

Art Unit: 1636

There does not appear to be any literal or implicit support in the originally filed claims or specification for claiming an isolated oligonucleotide comprising at least 15 nucleotides and having the particular hybridization characteristics recited in the rejected claims. Therefore, the rejected claims comprise impermissible NEW MATTER.

Further, there is no basis for the skilled artisan to predictably envision even a single oligonucleotide sequence that will meet all of the hybridization requirements recited in the rejected claims. Thus, the skilled artisan would not have been able to envision a sufficient number of embodiments to describe the claimed genus of oligonucleotides having very particular binding characteristics.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter that the applicant regards as his invention.

Claims 5, 14, 16, 18 and 23-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These are new grounds of rejection.

Claim 5 is vague and indefinite in that the metes and bounds of the phrase "... wherein said SMRT co-repressor or peptide portion thereof is encoded by a polynucleotide having at least 80% sequence identity with SEQ ID NO: 4" are unclear. Is the polynucleotide recited in this phrase necessarily the same as the isolated polynucleotide that is being claimed or can it be a second polynucleotide (e.g. a different polynucleotide that encodes the SMRT protein, or portion thereof, and which is different from the claimed polynucleotide because of the degeneracy of the

Application/Control Number: 09/522,753

Art Unit: 1636

genetic code and/or because the two different polynucleotides comprise additional, different sequences from one another)?

Claim 14 recites a "first isolated polynucleotide encoding a SMRT co-repressor" and then recites that the first polynucleotide is selected from a Markush group of different polynucleotides. It is unclear how the nucleotides of part (d) can encode a SMRT co-repressor, or portion thereof, when they are *complementary* to sequences in parts (a)-(c) that actually do encode an SMRT co-repressor. Similarly, claim 16 also recites that the first polynucleotides of part (d) have 80% identity to the *complement* of sequences in parts (a)-(c).

Claim 23 is vague and indefinite in that the metes and bounds of the phrase "suitable stringency conditions" are unclear. The phrase is used in the context of an identified oligonucleotide comprising at least 15 nucleotides that hybridizes to a polynucleotide of claim 4, but not to a polynucleotide encoding SEQ ID NO: 11 or to a polynucleotide encoding an amino acid sequence consisting of amino acids 1031 to 2517 of SEQ ID NO: 5. The specification does not define these exact conditions and the skilled artisan has no basis to visualize what these "suitable" conditions might be.

Similarly, claim 25 specifies that the oligonucleotide of claim 23 hybridizes under "suitable stringency conditions" to a polynucleotide encoding SEQ ID NO: 5 or SEQ ID NO: 7, but does not hybridize to a polynucleotide encoding SEQ ID NO: 9.

Art Unit: 1636

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G. Leffers Jr., PhD whose telephone number is (571) 272-0772. The examiner can normally be reached on 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gerald G Leffers Jr., PhD Primary Examiner

Primary Examiner

Art Unit 1636

YLEFFERS AIT UIII 103

ggl

2004
02
:15:
98:
19
Apr
Mon

53-5.rge 09/522 753 Page 1	 	33: em_hog_mus: 34: em_hog_mus: 35: em_hog_mus: 35: em_hog_man: 35: em_hog_man: 37: em_hog_man: 37: em_hog_man: 43: em_hog_man		Pred. No. BCOre grea and is der	Regult Query No. Score Match Length DB ID Description	13215 100.0 8561 9 AF113003 12978 98.2 866 9 AF125672 11067 83.7 8388 10 AF113001 10373 5 83 0 844 10 AF13001	9894 74.9 7485 10 AF113002 7885 59.7 5489 9 HSU37146 4102 34.9 2490 9 S83390 4194 31.7 7499 9 A8028970	31.7 7750 10 MMUJS312 31.4 7540 6 AXS78069 31.4 7760 9 AP04209 30.6 8018 9 AP087856 30.3 8859 5 AP495886 28.3 194480 2 AC139377 26.3 254489 2 AC097560	16 3445 26.1 2181199 2 AC136560 17 3344.5 25.3 219319 2 AC121005 18 3178 24.0 2282 9 BC004326 19 3012 22.8 2284 10 BC047524 20 2891.5 21.9 205283 9 AC073916	21 2187 16.5 3120 9 AF303586 22 2155 16.3 1917 5 BCD54296 23 2091.5 15.8 6318 10 AB093281 24 1900 14.4 6521 9 AB019524 25 1839 13.9 4235 10 MUSRIP136	1687 12.8 1881 9 BC050594 1663.5 12.6 1090 9 BC05651 1633 12.4 1781 9 BC056662 1628.5 12.3 3065 5 BC049302 1396 10.6 161200 2 AC027706	1391 10.5 2944 9 AX127788 1272 9.6 3345 9 HSMB02410 1172.5 8.9 3947 9 AF303585 1162 8.8 133947 5 AL590153 1113 8.4 640 6 AX677743 1099 8.3 1246 3 AF17523	1076 8.1 602 6 BD21548 950 7.3 555 6 AX677866 932 7.1 550 9 HSU80750 830 6.7 748 6 AX753058 845 6.4 7410 6 BD021376	43 74.5 5.9 6.4 774.5 5.9 66.4 774.5 5.9 13535 46 760.5 5.8 13535 47 750 5.7 177 48 746.5 5.6 4087 50 743 5.6 16648
Mon Apr 19 08:15:02 2004	GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.	OM protein - nucleic search, using frame_plus_p2n model Run on: April 15, 2004, 22:23:25 ; Search time 20448 Seconds (without alignments) 5335.212 Million cell updates/sec	Ĕ	Scoring table: BLOSUM62 Kgapop 10.0 , Xgapext 0.5 Ygapop 10.0 , Ygapext 0.5 Fgapop 6.0 , Fgapext 7.0 Delop 6.0 , Delext 7.0	Searched: 3470272 segs, 21671516995 residues	Total number of hits satisfying chosen parameters: 6940544 Minimum DB seq length: 0 Maximum DB seq length: 2000000000	g: Minimu Maximu Listir	Command line parameters: -MODBL=frame+ p2n.model -DEV=xlh -Q=/cgn2_1/USPTO_spool/US09522753/runat_15042004_143737_17428/app_query.fasta_1.2695 -DB=GedEnEmbl - OFWT=fastap -SUFIX=rge -MINMATCH=0.1 -LOOPCL=0 -LOOPEXT=0 -UNITS=b1ts -START=1 -END=-1 -MATRIX=blosum62 -TRANS=hummat40.cdi -LIST=100 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=100 -MODE=LOCAL	-OUTPWT=pto -NORM=axt -HRAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000 -USER=US09522753 @CGN 1 11601 @runat 1504204 143737 17428 -NCPU=6 -ICPU=3 -NO MMAP -LARGEQUERY -NEG SCORES=0 -WAÎT -DSPBLOGN=0 -LONGLOG -DEV TIMEOUT=120 -WARN TIMEOUT=30 -THRRAPS=1 -XGAPOCP=10 -XGAPEXT=0.5 -PGAPOP=6 -FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELEXT=7	Database: GenEmbl:* 1: gb_ba:* 2: gb_htg:* 3: gb_in:*	4: gb_om:* 6: gb_ov:* 7: gb_pat:* 7: gb_ph:* 8: gb_pl:*	9: 9b pr:* 10: 9b pr:* 11: 9b pro:* 12: 9b pro:* 13: 9b pro:* 14: 9b pro:*	15: em_ba:* 16: em_fun:* 17: em_fun:* 19: em_in:* 20: em_em:*	21: em_or:* 22: em_ov:* 23: em_ov:* 24: em_ph:* 25: em_pl:* 26: em_rol:* 27: em_fs:* 28: em_un:*

υυ

0000 00

HORS Downes, M.R., Cgdantlich, P. and Evans, R.M. LE Direct Submission NINL Direct Submission NINL Submitted (11-EC-1998) Gene Expression Laboratory, The Salk Institute for Fiological Studies, 10010 North Torrey Pines Road, La Institute for Fiological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA Location/Qualifiers 1. em 61 / mol 1790="mRNA" / db xgef="mRNA" / db xgef="mRNA" / db xgef="mRNA" / db xgef="mRNA" / tisegtype="pituitary"	CDS 7.7855 2. 77855 7 function="transcriptional co-repressor" /note+"hSMRT alpha; longer isoform than previously reported: /note+"hSMRT alpha; longer isoform than previously reported: /note+"hSMRT alpha; longer isoform than previously reported: /note+"hSMRT alpha; longer isoform than previously /codin="sallening mediator of retinoic acid and thyroid hprodiain id="hand0046.1" /prodiain id="hand0046.1" /prodiain id="hand0046.1" /hrain lation="MSGSTQUNQOWRATEPRYPHSLSYPOIARTHTDVGLLEYOH HSRDWSHLSPGSTIQPORRESSILATORSLAGGSBULTORSLAGEPSPHTOPEL IESKERALLIPPILLEPPILATORSLAGGSBULTORSLAGGPSPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGPSPEREVYSEPPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGPSPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGGSBULTORSLAGGESPHTOPEL IESKERSLAGGESTQUNGOUSCAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	AUTOPHALY TODOGOST VET THINGLAND-PRIKY VEROK VOWNWANSEGERKET PREKEWOHPKN AUTOPHALY TODOGOST VET THINKOLGAND-PRIKY VEROK VOOROOGOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	YEHLIRGYGOTDAYESHIPLAPOPTESI PEGIPLDADAYATYEPHIAPPY LIKGYDTAALENGYTI INDY TIS GONHHWYA TAWAGRADHLEGUS PRESELALIN'A A GPRGTEDIAGOVHHWYA TIS GONHHWYA TAWAGRADHLEGUS PRESELALIN'A A GPRGTEDIAGOVHHWYA TOPOTPATWORLAY LIPTAPOPPSSRHSSSPLSFOGFTH LIKTATYSSBERERDROBREREKESI LIYSTYTYERAP IN REGTEGOSGSSGSGSG GGGGGSRPASHSSHAHOUSP IS PRYTODALORPS VLHNYGWGI ITAWESPKRYARERER TSTSGWRAAT PPPATHCPLGCTLLOVY PILMEPVIL, PKTSAYARERER PRADTGHA RAMERKOGSKPS 10 ELENSIGNTONY PILMEPVIL, PKTSAYARERER PRADTGHA RADDEHLEKTYGSKPS 10 ELENSIGY STORT PROPOSES PEGYREVSPVS PEGYREV PREVKHORP PR SASDEHREKTOSKPS 10 ELENSIGY STORT PROPOSES PEGYREVSPVS PEGYREV PROPUND GAPARISPHSCHORP OLD SPENKT STORT PROPUNDIER PESDIL GYTARGKKHOHOUN VILAGII SEVI TODY TRHIPOLLS APLP APLY SP PEGASCPYLDIRR PSSDLL PREPEDDH GAPARISPHSCHORP OLD SPENKT STORT SNAAM TRKALINTHRENE BEYN I SOPGTET FRINKA STORT SOF PEFFEKT LITES SNAAM TRKALINTHRENE BEYN I SOPGTET FRINKA IT TADOGREDHILT SPROMESS PENT S RODR HESVENK SCHOLD SPROME SCHOLD SPROMESS PENT SCHORP SKAN SEGGCIRR PREPENTING WAS SERVAKS PEGIA SCHORP SKON SCHORP PREPENT STANDER PREPENTINK THRALDGK SPROMAS PP PROL PROGREDA SPROME SPROME SCHORP PESSAR SKON SPROMAS PP PROL PROGREDA SPROME SPROME SCHORP PESSAR STANDELINK LOAG WAAS PP PROL PROGREDA SPROME SPROME SPROME SPROMESS PENT SPROME SPROMESS PP PROL PROGREDA SPROME SPROME SPROME SPROMESS PROFILED THREAD SPROMESS PP PROL PROGREDA SPROME SPROME SPROME SPROME SPROMESS PP PROL PROGREDA SPROME SPROME SPROME SPROME SPROMESS PROFILED THREAD SPROME SPROMESS PP PROL PROGREDA SPROME SPR	Alignment Scores: 28-259 Length: 8561 Pred. No.: 13715.00 Matches: 2517 Percent Similarity: 100.00% Conservative: 0
REFERENCE AUTHORS TITLE JOURNAL PEATURES SOUEC	.		ORIGIN	Alignment Pred. No.: Score: Percent Si
AC104627 Drosophil AE003490 Drosophil AC127533 Homo sapi AP005045 Streptomy AR16425 Sequence AC114730 Homo sapi U22016 Homo sapi AC026106 Homo sapi AC134821 Rattus no AC133464 Homo sapi AF124821 Rattus no AC133464 Homo sapi	AB089954 Micromono AC026106 Homo sapi AX697897 Sequence AX697897 Sequence AX697877 Sequence AX134881 Homo sapi AJ09022 Grapevine AJ09022 Grapevine AZ000547 Homo sapi AZ072604 Sequence UB2965 Streptomcy EX842574 Mycobacte EX842574 Mycobacte EX86020 Avermectin BD097649 A method AB013367 Streptomy AZ005034 Streptomy AZ005034 Streptomy AZ005034 Streptomy AZ005034 Streptomy	AC087366 Homo sapi AC139725 Danio rer AL939119 Streptomy AB093554 Streptomy AX600586 Sequence BX248342 Mycobacte AE01049 Streptomy AE07003 Mycobacte AE07003 Mycobacte AE071043 Streptomy AY211023 Streptomy AY211023 Streptomy AY211023 Streptomy AY211023 Streptomy AY04801 Bovine he U7829 Streptomy AE007164 Mycobacte AE07764 Mycobacte AE07764 Sequence AE07764 Sequence AE07764 Sequence AE07343 Sequence X11548 S pristinae X11548 Stristinae	MTS of retinoic acid and thyroid mplete cds. raniata; Vertebrata; Buteleostomi; atarrhini; Hominidae; Homo.	colear receptor corepressor SMRT (6), 2639-2644 (1999)
3 AC104627 3 AE003490 9 AC127533 6 AR16645 6 AC114730 2 AC12616 1 SC0393108 1 SC0393108 1 AF124821 9 AC133644 9 AC133644 9 AC133644	1 SC0339111 1 AB009954 2 AC08610 6 AX677987 2 AC144811 4 GF1209022 9 AP0002204 6 AX072504 6 AX072504 6 E38020 6 BD097649 1 AB002367	9 AC097386 5 AC19725 1 SC039119 6 AX603554 6 AX60586 1 AX60586 1 AX71024 1 AX71024 1 AY21024 1 AY21023 1 AY310323 1 AX8572028 1 SPSNBCGEN 1 SC0399114	8561 bp or alpha mRNA, comple :445451 human) azoa; Chordata; Crani azia; Primates; Catax 8561) Downes,M., Xie,W., G	uman and mouse nu Sci. U.S.A. 96 (
លលលលលលលលលលលលល ស្រល់ស្រល់ស្នងក្នុងក្នុងក្ន	កាលក្នុសក្នុសក្នុសក្នុសក្នុសក្នុ ក្នុងក្នុងក្នុងក្នុងក្នុងក្នុងក្នុងក្នុង	83.5 5.2 155343 81.5 5.1 15394 66.5 5.1 15397 66.5 5.0 305550 66.5 5.0 305550 66.5 5.0 305550 66.5 5.0 14457 66.5 5.0 138203 66.5 5.0 138203 67.5 6.0 139203 67.5 6.0 139203 67.6 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6	ALIGNMENTS AF113003 8561 bp mRNA linear home sapiens silencing mediator of retinoic acid home sapiens silencing mediator of retinoic acid AF113003 AF113003.1 G1:4454551 Home sapiens (human) Home sapiens (human) Bukaryota; Metazoa; Chordata; Craniata; Vertebrat Mammalia Butheria; Primates; Cararrhini; Hominici of Chapteria; Primates; Cararrhini; Hominici ordentlich, P., Downes, M., Xie, W., Genin, A., Spinn	Evans. K.M. Unique forms of h Proc. Natl. Acad. 99178941 10077563

υ

00000

RESULT 1 AF113003 LOCUS DEFINITION

ACCESSION VERSION KEYWORDS SOURCE ORGANISM

REFERENCE AUTHORS

TITLE JOURNAL MEDLINE PUBMED

	Page 3	ArgLysGlnArgeluLeuGlnGluArgMetGlnSerArgValGlyGlnArgGlySerGly 360	etSenAlaAlaArgSerGluHisGluValSerGluIleIleAspGlyLeuSer 	GluGinGluAsineuGluLysGluMetArgGlnLeuAlaVallleProProMetLeuTyr 400 	AspalaaspGl#GlnargileLysPheIleAsnWetAsnGlyLeuWetAlaAspProMet 420 	LysValTyrLygAspArgGlnValMetAsnMetTrpSerGluGlnGluLysGluThrPhe 440	ArgGluLysPhedetGlnHisProLysAsnPheGlyLeuIleAlaSerPheLeuGluArg 460 	LysThrvalalafilucysValLeuTyrTyrTyrLeuThrLysLysAsnGluAsnTyrLys 480	SerLeuValardhrgSerTyrArgArgArgGlyLysSerGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnGlnG	Ginginginginginginginginginginginginetproketprokrysersergingiugiulys 520 	AspGluLysGluLysGluLysGluAlaGluLysGluGluLysProGluValGluAss 540 	AspiyaGluAsgleuLeuLysGluLysThrAspAspThrSerGlyGluAspAsnAspGlu 560	LysGluAlaVaLAllaSerLysGlyArgLysThrAlaAsnSerGlnGlyArgArgLysGly 580 	ArgileThrArgHerMetAlaAenGluAlaAsnSerGluGluAlaileThrProGlnGln 600		BGJyLeuLeuGluHisGlyArgAsnTrpSerAlaileAlaArgMet 			ArgivelysiyefiysAlaProAlaAlaAlaAserGluGluAlaAlaPheProProValVal 700
1 1 1 0 0	-09-542-753-5.Fge	Oy 341 7	Oy 361 Db 1082	Oy 381 Db 1142	Oy 401	Qy 421 Db 1262	Oy 441	Qy 461 Db 1382	Oy 481	Qy 501 Db 1502	Qy 521 Db 1562	Qy 541 Db 1622	Qy 561 Db 1682	Oy 581 Db 1742	. Db 1802	Oy 621 Db 1862	Oy 641 Db 1922	. Oy 661 Db 1982	Oy 681
	#DO # 70:CT:00 CT	Local Similarity: 100.00% y Match: 100.00%	9-522-753-5 (1-2517) x AP113003 (1-8561) 1 MetSerGlySerThrGlnLeuValAlaGlnThrTrpArgAlaThrGluBroArgTyrPro	2 ProfitsSerieuseTryProvalGlnileAlaArgThrHisThrAspValGlyLeuLeu 40 CCCCACAGCTTTCCTTTTTTTTTTTTTTTTTTTTTTTTT	41 GlutyrdlnHisHisSerArgAspTyrAlaSerHisLeuSerProGlySerllelleGln 60		GlyLysSerGluMet 	ProLeuLeuArgPro 	SerProLeuLeuAlaThrGlyGlnProAlaGlySerGluAepLeuThrLysAepArgSer	LeuThrGlyLysleuGluProValSerProProSerProProHisThrAspProGluLeu 	161 GluLeuValProProArgLeuSerLyeGluGluLeulleGlnAsnMetAspArgValAsp 180	ArgGluileThrMetValGluGlnGlnileSerLysheuLysLysLysGlnGlnGlnLeu 	GluGluGluAlahlaLyBProProGluProGluLyBProValSerProProIleGlu 	221 SerlysHisArgSerLeuValGlnIleIleTyrAspGluAshArgLysLysLysAlaGluAla 240	241 AlaHisArgileLeuGludlyLeuGlyProGlnValGluLeuProLeuTyrAsnGlnPro 260	261 SerAspThrArgGlnTyrHisGluAsnIleLysIleAsnGlnAlaMetArgLysLysLysLysLysLyslyslyslyslyslyslyslyslyslyslyslyslysly	281 IleheutyrPhelysArgArgAsnHisAlaArglysGlnTrpLysGlniysPheCysGln 300 	301 ArgTyrAspGlnLeuMetGluAlaLeuGluLysLysValGluArgIleGluAsnAsnPro 320	321 ArgArgArgAlaLysGluSerLysValArgGluTyrTyrGluLysGlnPheProGluIle 340
>	4	Best Quer DB:	o-sa & a	8 8 8	è 8	상 원	දි දි	දි දි	දු ද	රු සි	8 3	දි සි	දු පු	දි දි	장 <u>유</u>	සි ර	8 8	දු දු	8 &

٠.

g

ठे

g

ò

g

ઠે

8 4 8 4 8 4 8 4 8 4

8686

g

8686

a

ઠે

유

ઠે

ò

õ

ઠે

요 수 요

2004
0
O
N
02
0
••
15
Н
**
9
13
ы
Ω
Apr
Mon

us-09-522-753-5.rge

ŧ

ACTION OF THE PRODUCT CONSTRUCTOR OF THE PROPERTY OF THE PROPE		QY 341 ArgLysGlnard6luLeuGlnGluArgMetGlnSerArgValGlyGlnArgGlySerGly 360 Db 1177 CGCAAGCAGCGGAGCTGCAGGCGATGCAGAGGGTGGGCCAGCGGGGGCATGGG 1233 QY 361 LeuSerMetSerAlaAlaArgSerGluHisGluValSerGluIleIleAspGlyLeuSer 380 Db 1234 CTGTCCATGTCGCCCCCCCAGCGAGCACGAGGTGTCAGAGATCATCGATGGCCTCTCA 1293	Oy 381 GluGInGluAstbeuGluLysGlnMetArgGlnLeuAlaVaIIIeProbroMetLeuTyr 400 Db 1294 GAGGAGAGAGTGGGCAGCTGGCCGCGCCCCCCCCCCCCC	Qy 421 LysVallyrLydasapargGlnValMetAsnMetTrpSerGluGlnGluLysGluThrPhe 440 Db 1414 AAGGTGTACAAAGACGCCAGGTCATGAACATGTGSAGGAGGAGGAGGAGGAAGGAGCCTTC 1473 Qy 441 ArgGluLysPheMetGlnHisProLysAsnPheGlyLeu1leAlaSerPheLeuGluArg 460 Db 1474 CGGGAGAAGTTGATGCAGGATCCCAAGAACTTTGGCCTGATCGCATCATTCCTGGAGAGG 1533	Oy 461 LysThrValAlffill(Oy 501 dlnGlnGlnGlnGlnGlnGlnGlnGlnProMetProArgSerSerGlnGluGluLys 520 Db 1654 CAGCAGCAGCAGCAGCAGCAGCCCATGCCCCGCAGCAGCAGCAGCAGAAA 1713 Db 1654 CAGCAGCAGCAGCAGCAGCAGCAGCCCATGCCCCGCAGCAGCAGCAGAAA 1713 Oy 521 AspGluLyGGluLyGGluAlaGluLyGGluGluGluCyBrroGluValGluAsn 540 Chill	Oy 541 AsplysGluAspleuleulysGluIvysThrAspAspThrSerdlyGluAspAsnAspGlu 560 Db 1774 GACAAGGAGTTCCTCAAGGAGAAGACGACGACCTCTCAGGGAGGACGACGACGAG 1833 Oy 561 LysGluAlayaRhlaSerLysGlyArgysThrAlaAsnSerGlnGlyArgArglysGly 580 Db 1834 AAGGAGGCTCTCCCAAAGGCCGCAAAACTGCCAACAGGAAGACGCAAAGGC 1893	Oy 581 ArgliefhrangerfaleabandlualaasnSerdludlualailefhrProdludin 600 1894 CGCATCACCCGGGCTAATGGCTAATGAGGCCAACAGCGAGGGCCATCACCCCCCAGCAG 1953 Qy 601 SeralaGluleahaSerMetGluleaAsnGluSerSerArgTrpfhrGluGluGluMet 620 Cy 61 SeralaGluleahaSerMetGluleaAsnGluSerSerArgTrpfhrGluGluGluMet 620
SHSHAHOHSPISPRYODALOGYBENTHANGARIANSERRATIONSERRATIONSERRATIONSER PRACTICAL STRONG STR	CONTRACTOR OF THE ACCORDANCE O	erus , s vije	e de la competit de la companya de l	na a ser en	ONLY OF THE ENGINEERING AND A STATE OF THE S		of a discount and a number of the angelon	unimate de la constanta de la
אָס מַשְׁמַ כָּי	SHSHAHQHSPISPRTQDALQQRBSVLHNTGMKGIITAVEBSKPTVLRSTSTSSPV ATFPRATHCPLGGTLGYVPTAMEVLLIKEAPRNYRERRRATGHALAKBPA LEBASSPSGSERELJUGYVPTAMEVLLIKEAPRNYRERRRATGHALAKBPA LEBASSPSGSERELJUGYVPTAMEVLLAPHASPDPRAPASASDPHR QSKPFSIQELRSLGYHGSSYSPEGTVEPVSPVSEPSLITHDKGLPKHLBELDKSH ELRRYQPGFYTTARGARAHLHENELPESOGSSSPLLGTARGVTAPGYTEPDHGAPARGS ITQOYTRHHQOLSAPLAPHYSPEGTSCPVLDLRRPSDLYLTBPDHGAPARGS EGGTKSSPENKTSVLGGSBDGIEPVSPPSGHTEPGHSKANYPLLXRDGEGTEPS SKSPGNTSQPPAPFSKLTESNAMVEKKQBINKKANTHRNEPEYNISQPGTEI PAITGTGALTATTGTGALTSTRWGLARJENGTSANYPLLXRDGEGDRPS VHSEGDCNRTFPLLCGGSENGTEPSPNAPLIMKLANGYDONESSPPEGLAGGBRPS VHSEGDCNRTFPLLCSQYFTLSDSE" SCOTES: 1.26e-254 Length: 8686 12978.00 Matches: 2487 Contest 2487 Iniliarity: 98.578 Contestvative: 3 Skinlarity: 98.578 Contestvative: 3 Skinlarity: 98.578 Contestvative: 3	98.21% Indels: 28 98.21% Gaps: 3 7. x AF125672 (1-8686) SerThrGlnLeuValAlaGlnThrTrpArgAlaThrGluProArgTyrPro		Proglakty Arganger Prosented Serial Wheelan Proglaker Control of Serial Canada Serial	GluPhelleGluSerLysArgProArgLeuGluLeuLeuProAspProLeuLeuArgPro GAGTTCATTGAAAGCAAGCGCCTCGGCTAGAGCTGCTGCCTGACCCCTGCTGCGACCG SerProLeuLeuAlaThrGlyGlnProAlaGlySerGluAspLeuThrLysAspArgSer HIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	LeuThrGlyLysLeuGlyCoversors LeuThrGlyLysLeuGlyCoversors LeuThrGlyLysLeuGlyCoversors LeuThrGlyLysLeuGlyCoversors LeuThrGlyLysLeuGlyCoversors LeuThrGlyLysGlyCoversors LeuThrGlyCoversors LeuThrGlyCoversors	GAGCTGGTGCCGCCACGGCTGTCCAAGAAGAACTGATCCAAAAATGGAACGGGTGGGACCACGGTGGAACAAAAATGAACCGGGTGGAACAAAAAAAA	dadgadgcTdcCaadcCdcCdadcCTGAdaaAgcCCGTGTCACCGCCCTTCAAG SerLysH1sArgSerLeuValGlnIleIleTTFTYASpGluAsnArgLysLysBysAlaGluAla [[][][][][][][][][][][][][][][][][][][

Pag	Wallisgium broakggluagalaa Promitiy Broala Proprobla Proprobla Proprobla Broak Adversory Broak and Broak Adversory Broak and Broak Adversory Broak B
-522-753-5.rge	990 svalHisGlubener 904 1000 optoprodelnative 905 1100 optoprodelnative 906 1102 ogcacacacacacacacacacacacacacacacacacaca
Mon Apr 19 08:15:02 2004	1914 AGGGCCGLGCTGCATGGAGCTGAATGAGGTTCTCCGTGGACGAGGAGAAAATGG 610 611 61
æ.	8 6 8 6 8 6 8 6 8 6 8 6 8 6 8 6 8 6 8 6

公司公司公司公司

8 & 8

8 8

ර සි ර

8 4 8 4 8 4 8 4 8 4 8

8 &

8 8 8 8 8

2004
×
ñ
07
in
:15
••
90
0
13
Apr
Mon

us-09-522-753-5.rge

Cy 2432 rValHisSerGliGlyAspCysAsnArgArgT	2452 pargprosersera	Db 7482 CAGGCCTCGTCGGCAGGTTCCACGCCATTCC Ov 2472 nAlaGlvValNMHAlaSerProProProC	7542 GGCGGGTGTCAT	2492 adityrrohishishishishishishishishishishishishish	Oy 2512 FIGURESARDSORDIGHTU 2517 Db 7662 ACTCTCCGACACAGAG 7677	8388 lencing mediat	31:4454547	SOURCE MUS MUSCLINE MODES MOUSE) ORGANISM MUSCULUS MOUSE, Characoa, Chordata, Crar Mammalla, Eutheria; Rodentia, Scii		MEDIJINE 91718941 REDIJINE 9177863 REFERENCE 2 (bases 1 cd 8188)	Direct Submission Submitted (11 DEC-1998) Gene Ex Institute for Biological Studie	FEATURES Location/Qualiflers 1. (4788 1.	/ MOJ TAPE= "LEAXON: 10090" / Lisque_type="spleen; bra / CDS	/ notes and the state of the st	/profitin id="AAD20944.1" /Drofitin id="AAD20944.1" /db_yref="G1:4454548" /trafallation="MGSGTQDYAQ1"	TENGPELBILDPULLRESPLIANT TENGPELBILDPULLRESPLIANT ELAPGELSPULANT IENGRESLIQUENREKABAHI ENGRESLIQUENREKABAHI PENTAT HIVETORITA POMEDREPENT	NAMA PERMOSENCE CONTROLOGISMOSENCE CONTROLOGISMOSENCE AVI PRINTYDADOORI KFINMISTEM FORLINGENCHATTITICA FORLINGENCE CONTROLOGISMOSENCE CONTROLOGISMOSE CONTROLOGISMOSENCE CONTROLOGISMOSE CONTROLOGISMOSENCE CONTROLOGISMOSE CONTROLOGISMOSENCE CO	TANGGERKGETTESMANEANHEET EHGRINGSALARMYGSKTVSOCKNFY PAAAGEETAFPPAAEDEEMEASGAS
6282 GGTGGAGCCCGTCAGCCTGTGAGCTCACCCAGTCTGACCCACGACGAGGGCTCCCCCAA 6341 2072 sHisheuGludeuhspLysSerHisheuGluGlyGluLeuhggProLysGlnProGl 2092	6342 GLACCTGGAAGAGGTCGACAAAAAGAGGACGAGGAGGCCCAAGCAGCAGG 6401 2092 vproValivsLeuglvGlvGlvGlaAlaAlaHisLeuproHisLeukrGProLeubroGluSe 2112		2112 rGlnbroserSerSerProLeuLeuGlnThralaProGlyValLy8GlyHi8GlnArgVa 2132	2132 IValThrLeunlaGlnHisIleSerGluValIleThrGlnAspTyrThrArgHisHisPr 2152	2152 oglndlinleuSerAlabroLeuBroAlabroLeuTyrSerPheProGlyAlaSerCysPr 2172	2172 OVALLeuAspleuArgArgProProSerAspleuTyrLeuProProProAspHisGlyAl 2192	2192 aProhlaArgGlySerProHisSerGluGlyGlyLysArgSerProGluProhsnLysTh 2212	2212 rSerValLeuGlyGlyGlyGluAspGlyIleGluProValSerProFroGluGlyMetTh 2232	2232 rGlubroGlyHisSerhrgSerAlaValTyrProLeubeuTyrArgAspGlyGluGlnTh 2252	2252 rGlubroserargMetGlySerLysSerProGlyAsnThrSerGlnProProAlaPhePh 2272	2272 eSeriysLeuThrGluSerAsnSerAlaMetValLysSeriysLysGlnGluIleAsnIy 2292	2292 sLysteuarnth-Hishsnargasngluproglutyrasnilessergluproglythrgl 2312	2312 ullepheasnMerProhlalleThrGlyThrGlyLeuWetThrTyrargSerGlnAlaVa 2332	2332 IGInGluHisAlaSerThrAsnMetGlyLeuGluAlaIleIleArgLysAlaLeuMetGl 2352	2352 ylysfyraspGlnTrpGluGluSerProProLeuSerAlaAsnalaPheAsnProLeuAs 2372	2372 nalaseralaserreuproalaalaMetProIleThralaalaaspGlyargseraspHi 2392	2392 SThribeuthrSerProGlyGlyGlyGlyGlyBalalysValSerGlyArgProserSera 2412	2412 GLysAlaLysSerProAlaProGlyLeuAlaSerGlyAspArgProProSerValSerSe 2432
දි දි	a 8	3 සි	සි සි	· & a	÷ 8	දි දු	දි දි	දි දි	ò 'q	දු පු	දි දි	è 8	දි දි	දි දි	දි දි	දු පු	දු පු	& g

2412 [WILLIAM [WILL] [W

		_	
	NSSDTESVPSPRSEAMKDTGPKPTGTEALPAATOPPVPPPEEPAVAPAEPSPVPDASG (PPSPEPSHHLPHDRLLWTRMNKKPRLLQLPRQRMPRSRSLRPRRSMWEKPEEPEASEE	δ 	
	PPESVKSDHKBETBEBPBDKAKGTEALETVSEAPLKVBEAGSKAAVTKGSSSGATODS DPSATCSADEVDRPRGGDKGRLLSPRPSLLTPPAGDPRASTSPOKPLDLKOLKORAAAT	qq	-
	PPIQVTKVHBPPREDTVPPKPVPPVPPPTQHLQPEGDVSQQSGGSPRGKSRSPVPPAE KRAKPARPDAPPREDVIOTEDDDDDGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	ð	
	HPLPIGETHDSARPVLPRPPISONPPLISSAKHPGVLBRQLGAISQGGWGVQLRVPHSE HAXBAMGDITWGIPLANDAYGTORAIGGSTWGIPSAPAADGSGYDGGTTWGTD	a a	1
	ADVLYKGT I SKI VEDESPERLING FRANCE OGGI I MALE ADVLYKGT I SKI VEDESPERLINGSKEDT ÞKGYV I YEGKKGHVLSYEGGMSVSQCSKE DRRSSSGPHETTA ÞKRHYNMRGRYGPHTFRSSG FRI MARA I ÞROHS BEI KROHHI Þ	ò	
	GSITQGIPRSYVRAQEDYLRREAKLIKREGTPPPPPPPPPPPPPLDFLGPLGPLKG	qq	н
	NETHING VALVARAGATION FROM THE TRANSPORT OF THE TRANSPORT	ò	
	NGAR'Y VE BLOAK RASELLI BUNGAR'E ISBILKASEV ITREFIFKLANGKSENDIG. DRKLIFSPREIAKSPHSTVPEHHPHPIS PYEHLLRGVTGVDLYRGHI PLAFDPTSIF CI DI BARAR VIT BUHI ARGENEURI VEDRY TERVYDRAR I BARGORI FARVYHRGAGARI	q 0	7
	3.F EIGHAGADHLING TERLEDE FERNING FERLING FERLING FERLING FERLICH FERLICH FERLICH FERLICH FERLING FERLICH FERLING FERLICH FERL	È	
	TIVERAD PURPETSSKRISSSFLISFEGGFTHLAKFTATSSSEKEKEKEKINGSTUTST TIVERAD FUNDOTEGGSGGGGGSSPASHTHQUEDDALQQALQQDSVLHYTSMKGV	do do	ન
	VISVEVEIPVLINKKSISISSEVÄRAATFPPATHIPULGGTLEGGYTTEGYVTLINKEVLILKE TERVARPERARVDAGHAFITTERPOREPASSESKSSERRAPPEAPATATARTPAKNI.	ò	
	APTIMAS PUERAK I SASULINGKAI LOSKER SI LOBLEKSUAT MISGAGIS PLOVERELSEYS SPSULTHOKGUSKPLEBLEKSHLEGELERKOPOPOPOMICA SABABAL PHLRPLPESQPSSSP I I Omb dot kginoniami a anti revit monambuldomi sode da ri vegena egintidi.	ପ୍ଧ	H
	DAGATE CHARACTORY LANGITUDE VITAGO I KANTENGUGE LEFENIS FEGENEVELDID. PREPEDLI LEPPEDHGT PARGESPHESEGGKKS PERESKYTSVLGSSEDA I EPVS PPEGMTEP KRISTORII VITA UTDERKOCHTATION TO DAKMOON PMEMENTER PARAMETER PARAMETER PARAMETER PARAMETER PARAMETER PARAMETER	è	
	LITTHRINEPEYNIGOPOTEE FINDEN TO TO A THE FALL ESUSAMY VASKADELIKK. LITTHRINEPEYNIGOPOTEE FINDEN TO TO ACTUAL TOROGAVOETAS TRINGLEAT I EKKALM CYNTONIEBENDEL OM MENTET HIS OFFEN EN METERMEN FORDOMY.	ପ୍ପ	ਜੇ
	GAL LOTHER FELGANAT NE LINASABLIFAANNET I I TAUGKALITALIE FEGGGRAKVOGK PSSKRAKSPAPULLASOURPPSVSKYHSEDOURTPELTINKVHEDRESSAGSTPFPYNP I INDI OAGINA DODDIGG A ACCEST ACESTUAKEDENET I COCKETT CACKET	ò	•••
misc_feature	1111387 Acloted in Output her information of the control o	ପ୍ର	Ä
METOLOGI	/HOUSE REGION: USING THE STATE DECAME STOOMED BY GenBank Accession Number AF113002"	ò	
OKIGIN	M Bernard	ପ୍ଧ	ä
**	5.54e-216 Length: 8388	ò	
Percent Similarity:	Conservative: 8	qq	ä
Query Match:		ò	•
US-09-522-753-5 (1-2517)	x AP113001 (1-8388)	qq	ř
	,	ò	••
626	ATTENDED TO THE TOTAL PROPERTY OF THE TOTAL	qq	'n
21	4 0	è	
989		ପ୍ଷ	Ä
		ŏ	•
746		g	ñ
Ov 61 ProglnA		ò	•
808		qq	ĭī
81		ò	•
986		අ	13
101		ò	
926		qa	2
Ov 121 SerProle	SerProLeuLeuAlaThrGlvGlnProAlaGlvSerGluAspLeuThrLvsAspArgSer 140	à	4
986		qa	7
		ò	

1165 1345 1405 1285 1465 1585 1705 1765 1885 1945 2002 1825 2065 200 240 320 380 400 480 220 260 280 360 420 440 460 TGGAGCCTGTGTCTCCCCAGTCCCCCGCACGCTGACCTGAGCTA Leumet Gluala Leuglulysiya Yalgluargilegluasnaban Pro .euGluProValSerProProSerProProHisThrAspProGluLeu AlaLysProProGluProGluLysProValSerProProIleGlu BapargGinvalMetasnwetTrpSerGiuGinGlulysGluThrPhe AspalaaspGlmglnArgIleLysPheIleAsnMetAsnGlyLeuMetAlaaspProMet 301 ArgTyrAspGli ||||||||||| |526 CGCTATGACCAG 161 GluLeuValPre AlaHisArgile LeuThrGlyLy 11111 1046 CTGGCAGGCAAQ ArgGluIleTh GluciuciuAl 221 SerLysHisard .586 CGAAGGAGGGC 1646 CGCAAGCAGCGG GACGCGGACCAC 1106 GAGCTGGCGCC 166 CGTGAGATCAC .346 GCACACCGGATO TCTGACACACG SerAspThrArg IleLeuTyrPh .466 ATCTTGTACTT LeuSerMetSe CTCTCCATGTCC GluGlnGluAsr GAGCAGGAGAA 1406 181 201 1226 241 261 281 341 904 994 401 826 900 361 381 461

501 GlnGlnGlnGlnGlnGlnGlnGlnGlnGlnProMetProArgSerSerGlnGluGluLys 520

· · · · · · · · · · · · · · · · · · ·	3166 GCCAGAGGGGGGGGGGGGGGGGGGGGGGGGGGGGAGAGAGGGAGA		887 actudiyalaleniyasalacıliyselyscilolyoliyserciyargalatırırırA1 906 1888 idilli	alysserserd Malaprodinaspseraspserseralathropseralabspdluva	IASPG uAlaG G yG yAspiyaAsnaydenleuSsrProkrgProSerieuLeuTh 	rProThrGlyAdpProArgAlaAsnAlaSerProGlnLysProLeuAspLeuLysGlnLe	ulysglnhrgalhalanlalleProProlleglnValThriysValHisGluProProAr 	gGluhsphlahmProfinklysProhlaProbrohlaProbrohrohlabheudl [nProgluserAmpAlaProglnGinProglySerSerProArgolyLyGsSerArgSerProgrammer	oAlabroprokladaplysgluAlaphakladladladladladladladladladladladladladl	odlydapProkrotysTrpThrSerdlyLeuProPhaProValPr 	OProArgGluv#IIIalysAlaSerProHisAlaProAspProSerAlaPheSerTyrAl 	aProProd1/HimprolenBroLeudisAspThrAlaArgFroValleuProAr 	9ProProThrI 1958=RanBroProProLeuI leSerSerAlaLyBHisProSerValLe	uGluargGini#GlyaLaileSerGinGlyMetSerValGinLeuHisValProTy 		DETOUGHEN BLOOM TAY TO THE TOTAL TO THE TOTAL TO		1197 yThralaLeuGTestValProGlyGlySerileThriysGlyIleProSerThrargVa 1217
a terminal a cons	2173 Db Qy	2233 Db	560 Db	580 0Y 2353	600 OY 2413	620 OY 2473 Db	640 QY 2533	660 Db Db 2593	680 QY 2653 DD	700 QY 2713	720 OY 2773 Db	ಸಿಕೆಗು ಮಾಗ್ ಕೆ ಚಿತಿಗೆ ಒಗಕು	759 Oy 2893	777 OY 2944 BD	797 QY 2998 Db	817	837 GY 3114	857 QY 3165 Db	868 DD
		521 AspGluLysGluLysGluLysGluLysGluLysGluGluGluGluGluLysProGluValGluAsn:::	541 AsplysGluAspleuLeuLysGluLysThrAspAspThrSerGlyGluAspAsnAspGlu:::	561 LysGlualaValAlaSerLysGlyArgLysThrAlaAsnSerGlnGlyArgArgLysGly 	581 ArgileThrargSerMetalaAsnGlualaAsnSerGluGluAlaileThrProGlnGln 	601 SeralagluLeualaSerMetGluLeuasnGluSerSerargTrpThrGluGluMet :::	621 GluthralaLystysGlyLeuLeuGluHisGlyArgAsnTrpSeralaIleAlaArgMet	641 ValGlySerLysThrValSerGlnCysLysAsnPheTyrPheAsnTyrLysLysArgGln 	661 ABRILGUASPGIUIIELGUGINGINHISLYSLEULYSMETGIULYSGIUARGASNAIAARG 	681 ArgLysLysLysLysBysalaProAlaAlaAlaSerGluGluAlaAlaPheProProValVal 	701 GluaspGluGlumetGlualaSerGlyValSerGlyAsnGluGluGlumetValGluGluGlumetValGluGluGlumetValGluGluGlumetValGluGlumetValGluGlumetValGluGlumetValGluGlumetValGluGlumetValGluGlumetValGluGlumetValGluGlumetValGl	721 AlaGluAlaLeuHisAlaSerGlyAsnGluValProArgGlyGluCysSerGlyPro 	740 AlaThrValAsnAsnSerSerAspThrGluSerIleProSerProHisThrGluAlaAla	760 LyshapthrGlyGlnAenGlyProLysProProAlaThrLeuGlyAlaAspGly	778 ProProProGlyProProThrProProArgArgThrSerArgAlaProIleGluProThr	798 ProalaserGlualaThrGlyalaProThrProProAlaProProSerProSerAla	818 ProProProValValProLysGluGluLysGluGluGluThrAlaAlaAlaProProVal	838 GluGluGlyGluGluGlnLyBProProAlaAlaGluGluLeuAlaValAspThrGlyLyB	858 Ala-GluGluPro
	ብ	පි ජි	පි පි	8 8	දු ද	<u>ድ</u>	8 8	පි පි	8 %	\$ B	දි දි	ራ ብ	පි පි	& 8	<i>ት</i> ብ	è 4	8 8	8 8	ò

8 8 6 8 6

8 6 8 6 8

5 B 5 B 5 B 5

원 상

සි පි

ል ጵ

8 6 8 6 8

셤

ઠે

8 & 8

GATCAACAAAAACTCAACACCCACAACCGGAACGAGCCAGAATACATATTGGCCAGGCC 7416 OGIYThrGlulispheAsnMetProAlaileThrGlyThrGlyLeuMetThrTyrArgSe 2329	234	### TYTAS POLITY TO THE WAS TO THE WAS TALKED AND A WAS TALKED AND A WAS TO THE WAS TALKED AND A WAS TO THE WAS TALKED AND A WAS TO THE WAS TO	AGGCCCATACTGCCGCTGCTATGCCCATAACCACGGCGGCGGCGGCGGCTATGCCCATAACCACTGCTGCTGCTATGCCCATAACCACTGCTGACGG	######################################	gProSerSerAfflysAlaLysSerProAlaProGlyLeuAlaSerGlyAspArgFroPr 2428 	rServalhisSerGluGlyAspCysAsnArgArgThrProLeuThrAsnAr 2448	uamargproserseraladlyserThrProPheProTyrAenProLeull 2468	uGHAlaglyvalmetalaserProProProProGlyLeuProAlaglyse 2488	UATEGLYProhishishishlatrpAspGluGluProLysProLeuleuCysSe 2508	uthfleuSerkepSerGlu 2517 	8544 bp mRNA linear ROD 04-APR-1999	ongr extended isolorm (smrte) mkNA, o	s diouse mouse) s / Menzoa; Chordata; Craniata; Vertebrata; Buteleostomi; Nthiria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	1 (bases 1 td 8544) Park, E.J., Schroen, D.J., Yang, M., Li, H., Li, L. and Chen, J.D. SMTPs, a silenting mediator for retinoid and thyroid hormone receptors-extended isoform that is more related to the nuclear		2 (bases 1 to 8544) Chen, J.D. Direct Submission Submitted (03 ESB-1999) Pharmacology and Molecular Toxicology,	of Massachusetts Medical School, 55 Lake Avenue North, MA 01655, USA hoatign/Qualifiers
DD 7357 Qy 2309 Db 7417	Qy 2329 Db 7477	OY 23499	Db 7597	OY 2388 Y	Qy 2408 Db 7717	Oy 2428 OSerValSerSerVa	Oy 2448 gValTrpGluAd Db 7837 TGTGTGGGAGG	Oy 2468 eMetargleug	Oy 2488 rG1yProLeuAl	Oy 2508 rGlnTyrGluTh Db 8017 ACAGTATGAGAG	RESULT 4 AF125671 LOCUS DEFINITION	ACCESSION VERSION KEYWORDS	SOURCE ORGANISM	REFERENCE AUTHORS TITLE	JOURNAL FACT JOURNAL PEO MEDLINE 991 PUBMED 100	REFERENCE AUTHORS TITLE JOURNAL	FEATURES
TACCCTCATGGAGCCCGTCCTGTTACCCAAGGAGACCTCCCGGGTCGCCCGGGCCGAGCG GProArgAlaAspThrGlyHisAlaPheLeuAlaLy8ProProAlaArgSerGlyLeuGl	6352 GGCCCGGGTGGACGCTGGCCTTTCTTACCAAACCCCCGGGGCCGGGA 8402 1970 uProAlaSerSerProSerLysGlySerGluProArgProLeuValProProValSerGl 1990	1990 YHISALATHIBALAARGTHEPOALALASABALEUALABEOHISHIBALASSEPEOAS 2010	2010 pProProAlaProProAlaSerAlaSerAspProHigArgGluLysThrGlnSerLysPr 2030	2030 oPheSerIleGlnGluLeuGluLeuArgSerLeuGlyTyrH18GlySerSerTyrSe 2049	2049 rProGluGlyValGluProValSerProValSerSerProSerLeuThrHisAspLysGl 2069	VicuprolysHisLeuGluGluGluceuAspLysSerHisLeuGluGlyGluLeuArgProLy	GCICICCCAAACCICIGGGAAGAAGAAGAAGAAGAAGACAACTIGGAAGAGAAGCIGCGGGAAAAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA	GCAGCCAGGCCCCATGAAGCTCAGGGCGAAGGCTGCCCATCTCCCCACATCTGCGGGCCACT uProGluSerGlnProSerSerSerProLeuLeuGlnThrAlaProGlyValLysGlyH1 	6820 GCCCGAGAGAGCCGCCGTCATCCAGGCCCCCCCCGGAGGGTCAGCCCGGAGGGTCA 8879 2129 sGlnargvalvalThrLeuAlaGlnHislleSerGluValIleThrGlnAspTyrThrAr 2149 [C. Abrical Carlotting Collaboration Canada Carlotting C		2189 PHisGlyAlaProAlaArgGlySerProHisSerGluGlyGlyLysArgSerProGluPr 2209	2209 oAsniysThrSerValLeuGlyGlyGlyGluAspGlyIleGluProValSerProProGl 2229	2229 uGlymetnhrGluProGlyHisserArgSerAlaValTyrProLeuLeuTyrArgAspGl 2249 	2249 yGluGlnThrGluProSerArgMetGlySerLysSerProGlyAsnThrSerGlnProPr 2269	2269 OAlaPhePheSerLygLeuThrGluSerAsnSerAlaMetValLygSerLygLygGlnGl 2289	2289 ulleAsnLysLysLeuAsnThrHisAsnArgAsnGluProGluTyrAsnlleSerGlnPr 2309

8 6 8 6 8 6 8 6 8 6 8 6 8 6 8 6 8 6

	Oy 21 ProHisserLeugerTyrProValGln11eAlaArgThrHisThrAspValGlyLeuLeu 40	Qy 41 GluTyrGlnHi HIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Oy 61 ProgladrgargroserLeukeuSerGlubheGlabroGlyAsnGlubrgSerGln 80	Oy 81 GluLeuHisLeuBrgProGluSerHisSerTyrLeuProGluLeuGlyLysSerGluMet 100	101 GlubhelleGluBerlysArgProArgLeuGluLeuLeuProAspProLeuLeuArgPro	Oy 121 SerProLeuleuHlaThrGlyGlnProAlaGlySerGluAspLeuThrLysAspArgSer 140	Oy 141 LeuThrGlyLyefeuGluProValSerProProSerProProHisThrAspProGluLeu 160	Oy 161 GluLeuValPrdProArgLeuSerLysGluGluLeuIleGlnAsnMetAspArgVal 179	Oy 180 Aspargduil dhrMetValGluGlnGlnIleSerLysLeuLysLysLysGluGlnGlnGln 199	Qy 200 LeugluglugluglahalalysProbroglubroglulysProvalSerProbrolle 219	Oy 220 GluSerLysHiskrigserLeuValGlnileilefyrAspGluAsnargLysLysAlaGlu 239	Oy 240 AlaAlaHisArcalleLeuGluGlyVeuGlyProGlnYalGluLeuProLeuTyrAsnGln 259	Qy 260 ProSerAspTh.ArgGlnTyrHisGluAsnileLysileAsnGlnAlaMetArgLysLys 279	280 LeulleLeuTyngheLysargargargashtisalaargLysGlnTrpLysGlnLysPheCys 1000 CTGATCTTGTAGTTTAAGCGGAAGAACCACGCGCAAGCAGCAGCAGCAGCGCTTCTGC	Oy 300 GlahrgfrasgjalnfeuwerGluhlaleuGlulurstysvalGluhrgflaGluhannan 319	Qy 320 ProArgArgArgArgArgArgArgArgArgArgArgArgArgA	Db 1180 ATCCGCAACCAAGCAAGCACCAAGCAAGCCAAGCATGCAGACCAAGCATGGCAGCTTTTTTTT	-
source 1 8544	or/ db/	gene / gene="Smrte" CDS 160. 7548 /gene="Smrte"	/function="transcriptional corepressor" /note="SMRTe" /codon_start=1 /codon_start=1 /produce="silencing mediator of retinoic acid and thyroid hormone receptor extended isoform		TESKRRPILELPDTLIRPSPLIANGQPSGSEDLTKRKGQDLEEPVSPPSPPADPEL ELAPSRLSKEELLQNILDRYDKPTRTTMYBQQDSKKKKKQQQLEBERAKPPBEPBERVYSEP PIESKRRSLVQI I VDERKKARAHTLEGIGPOVBLPLVNGSSDTRQYHRVIKINQA MRKKLILYPKRRNHARKQMRPCQRYDQMENWKVER I ENNPRRRAKESKVREYY	EKQFPEIRKQRELQERMQSRVGQRGSGLSMSAARSEHEVSEIIDGLSEQENLEKQMRQ LAVIRHVYRRDQQRIKFINNMGLMDDPWKYYGDRQVTNMMSEQERDFTEREKRMQHPKN FGLILASFLERKTVAECVLYYLTKKNENYKSIVRRSYRRGKSQQQQQQQQQQQQQQ ARGSGSEREKREKREKREKREKDRADKRERKOJEKRGILASFUSRK	TANSOGRRKGRITRSMANEANHEETATPOOSSBLASMENNESSRWTEEEMETAKKGLL EHGRNWGAITARWGSRTVSOCKNFYFWYKKRONLDBILOCHKLASKEKRNARKKKYT PAAASEETAFPPAEDEEMEAGASANEEELAEREASGASGNEVPRVGECSGPAVN NSSDTESVPSFRSEATKOTGVRKYGTEALPAADPPPEPEPAAPRESEY	PPSPEPSPAAPPATUDKDBQBAPAAPPQTEDAKEQKSEAERIDVGKPERPEASEE PPBSVKSDHKEBTEREPERKAKGTBAIETVBBAPLKVEBAGSKAAVTKGSSSGATQDS BDSSATCSABFYDEPRGDEKGENERELISPREBASTSPSPGYFDLDKKGKARAAI DDTVTKYAUBDDBPFATUDEDEVIDENDEVIALOBPSPATATACOGGSG	EARYPAPPAGOYRISPHAGHTLPSHPRENTYNGYGOGOGOGOGOGOGOGOGOGOGOGOGOGOGOGOGOGO	LISKT VGEDSE SEKLIKRARDI I KGANKAN LIB BGGNS VÇÇGKEDENESSGUP PHETAALEKRYTÜMMEGRYCRITTISASI TEGINMERA I PEGISEPHLKEGIHI KGS I TÜĞIL RSYVBAQEDYLRREAKLLKREGTPPPPPPPRDLITETYKPRPLDPLGPLKLKPTHEGVV ATVKRAGRSI FILEI PREBLIKTTBLPLPLARPELKGGST TOGTPLKKROARSSTKKKIDV ATVKRAGRSI FILEI PREBLIKTTBLPLPLARPEKEGST TOGTPLKKROARSSTKKKIDV	AS I GASPOKE FRANKLING MANAGAMERAK I BESSINGSI SESAKGSI I KRAFV V V PERIOR KANAGASI KRAFV V V PERIOR KANAGASI KRAFV V V PERIOR KANAGASI KRAFV V V PERIOR KANAGA PENGHUR KANAGAYA KANAGA	TAPPPESSRIESSPRESSPRESPRESTALIN ELSGYPHULVUVPTAUFGTPATALLE TAPPPESSRIESSPRESSPRESPRESPRESPRESPRESPRESTRE WRPGTEQSSRIESSPRESSPRESHTQUALQQRESVLINTSMKGVVTSVERGT WRPGTEQSSGRAGGSSRPASHTHQHSPISPRTQDALQQRESVLINTSMKGVVTSVERGT PVTARFTSFRESPREPATTPEPLGTILEGYTLINEPVLINTSMKGVVTSVERGT WRCHART WROENAPPRESPRESPRESPRESPRESPRESPRESPRESPRESPRE	VOORHELIN FAMERANS OR MOSE FENSINE TANTE TANTE TRANSFERMEN FENSINE FOR THE VOORHELING FENSINE			ignment Scores: 3.116-211 ore: 10832.50 10832.50 87.94\$ st. Local Similarity: 84.41\$ ery Match:	US-09-522-753-5 (1-2517) x AF125671 (1-8544) Qy	160 AIGICAGAAICCACACACACACACACACACAGACAGAGGGGGGGG

Mon	Apr 19 08:15:02 2004	-09-522-753-5.rge	Page 16
		and district	
ठ ह		Db 2365	
g 8	1300 ICTGAGGGAGGAACCTGGAGAAGGAGGGGCCGGGGGGGGGG	Qy 759 AlaLysAspThr	AginasnglyProLysProProAlaThrLeuGlyAlaAsp 776
e 6	TACGACGC-GACCAGCAGAGGATCAGTCATCAACATGAATGGACTCATGGATGACCCC	2425 ACGAAGGACACT	GGGCCTAAACCCACTGGCACTGAAGCATTGCCCGCTGCC 2475
දු දු	420 MetLysValTyrLysAspArgGlnValMetAsnMetTrpSerGluGlnGluLysGluThr 439	Db 2476 ACCAGCCACC	
රි සි	440 PheArgGluLysPheNetGlnHisProLysAanPheGlyLeulleAlaSerPheLeuGlu 459	Qy 797 ThrProAlaSer 1:: Db 2530 TCCCCAGTCCCT	<pre>JualaThrGlyalaProThrProProProAlaProProSerProSer 816 :: :: ::: ::: </pre>
ે કે ક	ArgiveThirValAlaGluCysValleuTyrTyrTyrLeuThirLysIysBanGluAsnTyr	dy 817 AlaProProProProProProProProProProProProProP	
3 · &	LysSerLeuvalArgArgSerTyrArgArgArgGlyLysSerGlnGlnGlnGlnGlnGlnFll	Qy 837 ValGluGluGluGly	ingluginiysproproalaalaglugiuleualayalaspthrgiy 856 :
a & B	1597 AAGAGCTIGGTGAGGCGGAGCTATCGGCGCCGTGGCAAGAGCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC	0y 857 LygalaGluGluG 	ro
<u>ብ</u> ሪ	1657 CAACAACAGCAGCAGCAGCAGCAGGAGGAGGAGGAGGAGG	898	
; 4 <u>6</u>	:::	Db 2758	AAGAGCCTGAAGACAAAGCCAAGGCACAGAGGCCATTGAAACTGTG 2817 eutysalagluiysiyaggiuglyglySerglyArgalathrthr 905
& 90	540 AsnasplysGluaspleuteulysGlutysThraspaspThrSerGlyGluAspAsnasp 559	DD 2818	
કે ક	560 GluLyGGluAlaValAlaSerLyGGlyArgLygThrAlaAsnSerGlnGlyArgArgLyg 579	Oy 906 Db 2872	AlaLysSerSerfilyAlaProGinAspSerAspSerSerAlaThrCysSerAlaAspG1u 925
8 &	GlyArgileThrArgSerMetAlaAsnGluAlaAsnSerGluGluAla11eThrProGln	Oy 926 Db 2932	Valaspglualagluglyglydspiryasnargieuleuserproargproserleuleu 945
요 음 음	1885 GGCCGTATCACGCGCTCCATGGCCAACGAGGCCAACCATGAGGAGACAGCCACCCCCACAG 1944	Oy 946	ThrprothrdlykapproArgAlaAsnAlaSerProGlnLysProLeuAspLeuLysGln 965
h 유	CARACTICAGAGCTGGCTTCCATGGAGATGAACGAGAGTTCTCGCTGGACTGAGAAAGA	Dp 5393	ATCCCCGGGCCAGTACCTCGCCCCAGAAGCCGCTGGACCTGAAGCAG 3051 HaalaalailebroproileginvalthrLv8valHisGlubrobro 985
රු සි	620 MetGluthrAlaLysLysGlyLeuLeuGluHisGlyArgAsnTrpSerAlalleAlaArg 639	DD 3052	310
දු පු	640 MetValGlySerLysThrValSerGlnCysLysAsnPheTyrPheAsnTyrLysLysArg 659	0y 986 ArgGluAspAlæ 	
કે ક	GlnAsnLeuAspGluIleLeuGlnGlnHisiyeLeuLysWetGluLyi 	Oy 1006 GlnProGluSer	NspalaProGinGinProGiySerSerProArgGlylysSerArgSer 1025
3 & 8	ArghrgLysLysLysLyslyslaProklaklaSerGludluklaklaProkroval	Oy 1026 Db 3229	ProblaProProBlabspLysGlu
a &	2185 CGGAGGAAGAAGAAGAAGACCCCAGCTGGGGGGAGGGGGGGG	ОУ 1038	GlualaGinLysteuProGlyAspProProCysTrpThrSerGlyLeuProPheProVal 1057
q	GCTGAGGACGAAGGAAGGAACAGCGCAAGTGCCAATGAGGAAGAGCTGGCGGA	Oy 1058	
Oy Dp	720 GlualaGlualaLeuHisAlaSerGlyABnGluValProArgGlyGluCysSerGly 738	Db 3343	
ò	739 ProAlaThrValAsnAsnSerSerAspThrGluSerIleProSerProHisThrGluAla 758	Oy 1078	Alektorototamiertoleurro

Page	1415 The Process of the Control of t
9-522-753-5.	8 4 8 4 8 4 8 4 8 4 8 4 8 8 8 8 8 8 8 8
Mon Apr 19 08:15:02 2004 3397 ACACCCCCGGGTCACCCGCTGCCTCTGGGCCTCCAGGATAGTGCCCGGCCCGTCCTGCCA 3456	ACCCCCCGGTCACCCGCTCCCTCGGCTCCCCGGCTCCCCGGCCCGCCC

6 6 6 6 6 6 6 6 6 6 6 6 6 6 6

Mon	Apr 19 08:15:02 2004	09-522-753-5.rge		Page 18	
	·	***************************************			
& - <u>4</u>	1814 IleLeuThrSerThrThrThrValGluHisAlaProIleTrpArgFroGlyThrGluGln 1833	v ·			
දු දු	1834 SerSerGlySerSerGlySerSerGlyGlyGlyGlyGlyGlySerSerSerSerArgProAlaSer 1853	à d			
& A	1854 HisSerHisAlaHisGlnHisSerProllèSerProArgThrGlnAspAlaLeuGlnGln 1873	λ ₀ Α			
S S	ArgProSerValLeuHisAsnThrGlyMetLysGly1lelleThrA.	Q Q	2233 GluProGlyHiffSe 6691 GAGCCAGGACATGC		
<u>ئ</u> ۾	LysprothrvalleuArgSerThrSerThrSerThrSerProvalArgProAlaAlaThrPhe	8	Glubroserarg		
& £	1914 ProProAlaThrHisCysProLeuGlyGlyThrLeuAspGlyValTyrProThrLeuMet 1933	∀ €	2273 Serlysleuthus 	SluSerAsnSerAlaMetVallysSerLysLysGlnGlulleAsnLys 2292 	
} & £	GACCOSCERCOSTACOS AND STATEMENT OF STATEMENT	ò 8	2293 LysLeuAsnThiri 	LysLeudsnThEnisdandargdanGluProGluTyrAsnIleSerGlnProGlyThrGlu 2312 	
3 8 8	AspThrGlyHisAlaPheLeuAlaLysProProAlaArgSerGlyLeuGluProAlaSer	o d	2313 IlePheasmeep: 	roalailethrGlyThrGlyLeuMetThrTyrArgSerGlnAlaVal 2332 	
3 8 8	SerProSerLysGlySerGluProArgProLeuValProProValSerGlyHisAlaThr	λ a	2333 GlnGluhisalase 	erThräsnmetGlyLeuGlualallelleargLysalaLeumetGly 2352 	
1 & 2	994 IlealahrgThrProhlaLysasnLeuAlaProhisHisAlaSerProAspProProhla 1904 IlleHIHIHIHIHIHI:::	ò 4	2353 LYSTYLASDGISTA 	LystyraspolutryglugluserProProLeuseralaasnalaPheasnProLeuasn 2372 	
ે જે ઇ	014 ProproAlaSerAlaSerAspProHisArgGlulysThrGlnSerLysProPheSerIle	. & d	2373 AlaSerAlaserie 7108 GCCAGCGCCAGTCT	LeuproAlaAlaMetProlleThrAlaAlaAspGlyArgSerAsp 2391 	
}	Control Color of the Color of	à d	2392 HisThrLeuTh Se 	SerProGlyGlyGlyGlyUysAlaLysValSerGlyArgProSerSer 2411 	
1 & A	ValGluProValSerProValSerSerProSerLeuThrHisAspLy8GlyLeuProLy8 ValGluProValSerProValSerSerProSerLeuThrHisAspLy8GlyLeuProLy8 GTGGAGCCGATCAGCCGGGGGGGCTCCCCAGCAACAGAGGGGTCTCCAAA	à a	2412 Arglyshlalysse 7228 CGAAAAGCCAAGTC	rProAlaProGlyLeuAlaSerGlyAspArgProProSerValSer 	
දු දු	HisleugluGluLeuAspLysSerHisLeuGluGlyGluLeuArgProLysGlnProGly	S G	<u> </u>		
8 8	ProValLysLeuGlyGlyGlyGluAlaAlaHisLeuProHisLeuArgProLeuProGluSer ::	<i>ኤ</i> 8	2452 AspargProsense 		
& 8		ò 8	2472 GlnAlaGlyvalMe 		
& 8	ValThrLeuklaGlnHisIleSerGluValIleThrGlnAspTyrTh 	S &	2492 AlaGlyProHiffHi 7468 GCTGGTCCCCAGCA	HisalaTrpApgludluProLysProLeuLeuCysSerGlnTyrGlu 2511 	
` & €	53 GindinteuserAlabroLeuProAlabroLeuTyrSerPheProGlyAlaSerCysPro	<i>ኤ</i> ස	2512 ThrLeuSerAssSerGlu 	rglu 2517 gcgAG 7545	
3 &	ValleuAspleuArgArgProProSerAspleuTyrLeuProProAspHisGlyAla	RESULT 5 AF113002			

MVKSKKOEINKKLATHINRNEPEYNIGOPGTEI FNMPAITGAGLMTCRSGAVOEHASTN MOLLEÄITRKLMGKYDOMEBEPPELGAAR FNPLINASASLPPARAPETTATGAGSBHALTS POGGGGKAKVGSRPSSRAKSPARPGLASGDRPPSVSSWHSGGORGRATPLINRVMEDRP SSAGGFPFPYNPLIMRLOAGWASPPPPGLAAGSGPLAGPHAMDEEPKFLLCSGYET	GIN gument Scores: d. No.: 256e-192 re: 994.00 eent Similarity: 79199 t. Local Similarity: 79178 ry Match: 788	DB: US-09-522-753-5 (1-2517) x AF113002 (1-7465) QY	Qy 21 ProHisSerLeiderTyrProValGInIleAlaArgThrHisThrAspValGlyLeuLeu 40	Db 467 467 Qy 61 ProGlnArgArgArgArgProSerLeuLeuSerGluPheGlnProGlyAenGluArgSerGln 80 Db 467 467	Oy 81 GluLeuHisLeuArgProGluSerHisSerTyrLeuProGluLeuGlyLysSerGluMet 100 Db 467	SerProLeuLeuAlaThrGlyGlnProAlaGlySerGluAspLeuThrLysAspArgSer LeuThrGlyLygLeuGluProValSerProProSerProProHisThrAspProGluLeu	Qy 161 GluLeuValPrderoArgLeuSerLysGluGluLeuIleGlnAsnMetAspArgValAsp 180 Db 467 Qy 181 ArgGluIleThametValGluGlnGlnIleSerLysLeuLysLysLysGlnGlnGlnLeu 200 Db 467	Qy 201 Gludludlualanlanlanlanlanlanlanlanlanlanlanlanlan
LOCUS DEFINITION Mus musculus silencing mediator of retinoic acid and thyroid hormone receptor beta mRNA, complete cds. TECESSION AF113002	Mus musculus (house mouse) ISM Mus musculus Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. RS Ordentlich,P., Downes,M., Xie,W., Genin,A., Spinner,N.B. and Evans,R.M.	Unique forms of numan and mouse nuclear receptor corepressor SMRT JOURNAL Proc. Matl. Acad. Sci. U.S.A. 96 (6), 2639-2644 (1999) MEDLINE 99178941 REPUBNED 10077563 AUTHORS Downes,M.R., Ordentlich,P. and Evans,R.M. TITLE Direct Submission TOTALE Shimisted (11-InC-1008) Cons Formession Tehroston, The Call.	Institute for Biological Studies, 10010 North Torrey Pin Jolla, CA 92037, USA Location/Qualifiers (reganism="Mus musculus" //mol type="MRNA"	/db_xref="taxon:10090" /tissue_type="spleen; brain" 363. 7124 /function="transcriptional co-repressor" /note="mswRr bets; brees swr alpha isoform encoded by GenBank Accession Number AF11301"	/codon_start=1 /product="silenting mediator of retinoic acid and thyroid hormone receptor beta" /protein_id="AAD20945.1" /db_xref="staf4550" /translation="MSGSTOPAQCTWRAAEPRYPPHGISYPVQIARSHTPLYNQPSDT RQYHENIKINQAMRKKLILYFRRNNHARXQWEQRFCGRYDQLMRAWBKKVERIENNPR	REAKESKYREYTEKOPELOERMOSRVGORGSGLSMSAARSEHEVSELIDGL SEGENLEKOMEOLAVIPPULVDADORIKETINDKALVDDDRKYVLYDROYTMMRSEGER DTPEREKEMOHEKOPGLJASPELEKTVABCOVILYTUTKKANINYSSLVRRGKSOQ OQCOQOQOQOMARSSQEEKEBKEKEKEKERADKEEKODAENEKEELSKEKTDDTSGED NDEKERAVASKCRKTANSOGERKERTREMARANHERTATPOGSSELASMENDSSEW TEEEMETAKKGLLEHGRNWSAITREMANGSKTYROYGKRYFNYKKONLDEILOGHKLKM BKERNAARKKKKTTPAAASETTAPPAAEDEEMEASGASAMEBELARBARASOGNSCHEV PRVGECSGPAAVNNSSDTESVPSPRAEDEMEASGASAMEBELARBARASOGNSCHEV	APARES PYPDAGEPEPEREBHILAHPRILIWTRANKKPELLOLPROKRPERGERER MREKPEBPEASEKPPKSVKSDHKKETBER PENKKCTEAL ETVGEAPLKVEKAGSKAA VTKGSSGGATODOBOSATCASADEVDERGGOKKRILLSPREBLUFPAGDPRASTSPORT IDLKQLKQRAAAI PPIVTKVHEBPREDTVPRKPVPPPTQHLQPEGDVSQCSGP RGKSRSVPPDARAKARKPAPPAPPTGGRLPTBPRNSGGLPPPIPPERGTKTSPHA ADPSAFSYTPPGHPLPLGLIGHIGSARVENPPPEPIPSCARGGLPPPIPPERGTKGFBHA GWSVQLRVPHSGHAKAPMGPLTMGLPLANDPKKLGTALGSARFGKLBRQLAAISO GSVQLRVPHSGHAKAPMGPLTMGLPLANDPKKLGTALGSATSGSITKGLPSTRAADG PSYRGGITHQFPADULYKGTISRIVGEDSPRENDRARENILPRKHATISTEKKHILST	HERDICAL LIGHT AND AN AND AND AND AND AND AND AND AND

### Page	GAACCCGAAGGGGGACAGGCGGCTGCTCAACCAAGGCCCAGCCTCCTCACCCC OThYGLYASPPAGGGCAGGCTGCTGTCACCAAGGCCCAGCCTCCTCACCCC OTHYGLYASPPAGGGCAAGGCAGCTGCTGTCACCAAGGCCCAGCCTCCTCACCCC OTHYGLYASPPAGATACTCGCCCCAGAAGCCGCTGAAGACTAAAAAGTAAAAAAAA
-09-522-753-5.rg	3 & 3 & 3 & 3 & 3
a 0 0 6 6 7 8 8 8 8 8 8 9 0 0 7 9 8 11 0 0 1 2 1 2 1 5 1 8 8 8 8 8 8 8 8 8 9 0 0 1 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	AAAGAGGCCGTGGCCTCCAAAAGCCGCAAAACTGCCAAAGGCCGGCGGCGGAAAGGC 1433 ArgileThrargSerMetalaAsnGlualaAsnSerGluGlualaileThrProGlnGln 600

OAN COLOR OF THE C	CCCATACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
09-522-753-5.rge Oy 1358 Oy 1378 Oy 1415 Oy 1415 Oy 1415 Oy 1416 Oy 1416 Oy 1416 Oy 1416 Oy 1416 Oy 1515 Oy 1516	3505 3505 3505 3505 3505 3505 3505 3505
SCACCTACAGCC ArgSerProal	

8 & 8 &

1911

2660

5543 2011 5603 2031

8 6 8 6 8 6 8

8 6 6

ò

4760

Mon Apr

1754 4880 1774 4940 1794 5000 1814 5042 1834 5102 1854 5138 1874 5192 1894 5252

8 8 8

a

a

8 6

ઠે

g

8 6 8 6

8 %

HNTGEKGI ITAVEBSKPTVLRSTSTSSPVRPAATFPPATHCPLGGTLDGVYPTLMEPV LLDKÄAFRYNRPERREPAGDFAPASADPHRESTSGSKERSPRSVESGSERPREVLPVGGHATI ARTPAGNLAPHASEDPPAPASASDPHRESTGOSKPSTGELELKSCHGSSYSPEG VEPVSPSSPLTTBKGLPKHLBELDKSHLEGELRFKGGEVARLGGEAHLPHIRFLP BSQPRSSPLLGTAPGVKGHQKTVLACHISEVITODYTRHHPQOLSAPLPAPLYSFPG ASCPTLOIARRPPSDLYLPPEDHGAPAKGSPRSGPGKRSPERVIGGGEDGIEFVY SKCOTLINKRPPSDLYLPPEDHGAPARGSPRSGGKRSPRFSPSTTSSKSAWVK SKKOTINKLANTHNREPENNISOPGTEIFNRATTGTGATTRSGNAVUK SKKOTINKLANTHNREPENNISOPGTEIFNRATTGTGATTRSGNAVEHASTWGL GAKKGGRSSRKKSPARGIASGBRPSVSSVHSEGDCRRRTPLTNRVWEDRFSSAG STPFTYNPINKLAGAGVNASPPPGLAGPHHAMDEEFKPLLCSQYETLSSS ACN 44431 .4620 / Gene "SNRT" / Note" "Alternatively spliced insert"	### Alignment Socree: Paced. No.: 785.06 Matches: 1510
Db 6857 TGTCTCCTCAGTACACTCAGAGGGGACTGCAATCGCCGAACCCACCC	REFERENCE RESTORT 6 READ ACCESSACION READ READ Linear PRI 31-OCT-1995 RESTORTATION RUMBAN Linear PRI 31-OCT-1995 RECENSION 17146 Linear Linear

•		
4		
	-	
ì	7	3
٦	•	•
ı	•	
ì		١
	•	
ı		
•	_	į
•		•
•	1	•
i	_	
	_	
ć	3	١
•	,	i
į		4
	Ċ	ì
i	q	ĺ
į		1
i	Ć	j

2-753-5.rge Page 25	113	ACTWOLS SOURCE SOURCE SOURCE ORGANISM Homo sapiens CRANISM Homo sapiens Enkaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Enkaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; REPERENCE 1 (bases 1 t. 0.2930) AUTHORS Sande, S. and Privalsky, M.L.
Mon Apr 19 08:15:02 2004 us-09-52	1970 aleuGinGinArghroSerValieuHishamThrGiyMetryGiylislichthlava 1990 3039 ccrccAccacacaccCASTGTCTCTCTCACACACCACCACCACCACCCCCCCTCTTCTCTCTCTCTCCCCCC	2210 nLysThrSerValLeuGlyGlyGlyGluAspGlyIleGluProValSe 2210 nLysThrSerValLeuGlyGlyGlyGluAspGlyIleGluProValSe [

	Qy 1712 GlyLeuSerProdriggluSerSerLeudlaLeudsnTyralaalaGlyProdrigGlyIle 1731 	dy 1732 IleaspieuseaginvalproHisteuProValleuValProProThrProGlyThrPro 1751	Qy 1752 AlaThrAlaMeMaspArgLeuAlaTyrLeuProThrAlaProGlnProPheSerSerArg 1771 bb 603 GCCACCGCCATGEACCTCCCTCCCCCACCGCGCCCCTACAGCCGC 662	1772 HisSerSerSerProGlyGlyBroThrHisLeuThrLysProThrThr 	Oy 1792 SerSerSerGluargaspargaspargGluargaspargGluargaspargGluargGlu 1811 	Oy 1812 LysSerIleLedThrSerThrThrThrValGluHisAlaProlleTrpArgProGlyThr 1831	Oy 1832 GluGinSerSerSiySerSerGlySerSerGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyG	dy 1852 AlaserHisserHissalaHisdlnHisserProlIeserProkgThrGlnAspAlaLeu 1871	Oy 1872 GINGINAYGPYGSEYVALLEUHISABNThrGIYMELLYEGIYILEITEThrAlaYalGlu 1891	Qy 1892 ProSerLysProffhrValLeuArgSerThrSerThrSerProValArgProAlaAla 1911		Qy 1932 LeumetGlubrd ValleuleubrolysGlualabrokryValalaakgProGluargPro 1951 Db 1143 CrCarodaGcCcGerCTTGCrGcCCAAGGAGCCCCCCGGGGTCGCCGGCCCAGGCGCCC 1202	Oy 1952 ArgAlaAspThidlyHisAlaPheLeuAlaLysProProAlaArgSerGlyLeuGluPro 1971 Db 1203 GaAGCAGCAGCCATGCCTTCCTCGCCAAGCCCCCAGCCCGTCCGGGCTGGAGCCC 1262	1972 AlaSerSerPro	Oy 1992 AlaThrileal ArgThrProAlaLy8AsnLeuAlaProHi8Hi8AlaSerProAspPro 2011	2012 ProalabroprealaseralaseraspProHisargGluLysThrGlnSerLysFroPhe	 6	1503 GGGGTGGAGCC
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	TITLE Identification of TRACS (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors JOURNAL Mol. Endocrinol. 10 (7), 813-825 (1996)		FEATURES Location/Qualifiers Location/Qualifiers source 12930 /organism="Homo sapiens"	/mol_type="mRNA" /db_xref="taxon:9606" 1	CDS 456. 2765 //gene="T3" receptor-associating cofactor-1, TRAC-1" //note="This sequence comes from Fig. 4; Authors report detecting several TRAC alternative transcripts, TRAC-1"	/codon_start=1 /product="T3 receptor-associating cofactor-1" /protein_id="AAB50847.1" /db_xref="G1:1911770"	/translatioi="MAQRADMIRGHSPRESSIALNYAAGRKGIIDLGOVPHLPVIVPP TPGTPATAMORLAYLPTAQPPSRHSSSPLSPGGPHLIKVFTTSSERRRDDRER DRDREREKSIITSTTYVEHFTWRFTRGOSSGSGGGGGSSERPAHSHAGHSP ISPRTQDALQORPSVLHNTGMKGIITAVEPSTPTVLRSTSSTSSSVRPAATFPPATHCP	LGGTLUGAT FILMOTOTAL GALEKALEK VANF ERKEALGHAF LAANS BALBFADS ENN SERPELUGS YGHAATTARTHAKNIAPHIAS POPPAPPASAGDPHREKTOGKPESIQEL ELRSLGYHGSS YSPEGVEPVSPVSSPSLTHÖKGLPKHLEBLDKSHLEGELRFKQPGPV KLGGBAAHLPHLRPLPBSQPSSSPLLQTAPGYKGHQRVVTLAQHISSTITOYTHHP	OOLGAPLPAPINSEPERANCYVIDIARPPBBIXILPPDHARAFASEVESEVESEVEEN KTSVLGGGEDGIEPVSPPEGWTEPERSKAAVFLIXRDGEQTEPSRAGSKSPGNTSQP PAFFEKLTESNSAMVKGKKQENKKLAYTHRRNEPEYNISQPGTEIFNNFALTGTGLAYT YRSQAVQEHASTNMGLEAIIRKALMGGGGKAKVSGRPSSRKAKSPAPGLASGDRPPSV	SSYABEGOCKREPLINKVWENRPSSAGSIPFFFYNFLIMKLGAGVWASFFFFGLFAGS GPLAGAHHAWDEEPKPLLCSQYETLSDSE" ORIGIN	8.84e-86 4612.00 94.38%	Mismatches: Indels: Gaps:	US-09-522-753-5 (1-2517) x 883390 (1-2930) Qy 1592 IleAlaLy8SerPrOHi8SerThrValProGluHi8Hi8ProHi8ProlleSerProTyr 1611	carcrccccrar sileProLeuAla	Db 183 GAGCACCTGCTTCGGGGGCGAGACCTGTATCGCAGCCACATCCCCTGGCC 242 Oy 1632 PheaspProThrSerlleProArgGlyIleProLeuAspAlaAlaAlaAlaTyTyTLeu 1651	1652 ProArgHisleuAlaProAsnProThrTyrProHisleuTyrProProTyrLeuIlaArg 1652 ProArgHisleuAlaProAsnProThrTyrProHisleuTyrProProTyrLeuIlaArg 303 ccccqacAcccccqAcccCAccraccCAccraccCAccracCAccracCAccracCACCTACCCCACACCCCAACCCCAACCCCAACCACCTACCCCAACCACC	1672 GIYTYrProAspThrAlaAlaLeuGluAsnArgGlnThrIleIleAsnAspTh 	Oy 1692 SerGinGinMetHisHisAsnThrAlaThrAlaMetAlaGlnArgAlaAspMetLeuArg 1711